NCT03301805尚未招募2 期
A Phase II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Gemcitabine Monotherapy in Patients With Advanced Inoperable or Metastatic Pancreatic Cancer
Rgene Corporation0 个研究点目标入组 40 人开始时间: 2026年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 主要终点
- Part I: Dose-limiting toxicity (DLT) observation
研究概览
简要总结
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy at the recommended dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 20 - 80 years old at the time of signing the ICF.
- •Patients with pathologically proved adenocarcinoma of pancreatic cancer and diagnosed with inoperable/metastatic disease (previous systemic chemotherapy, neoadjuvant or adjuvant gemcitabine are acceptable, unless
排除标准
- •Eastern Cooperative Oncology Group (ECOG) performance status of 1 to
- •Adequate hematologic function defined as: absolute neutrophil count (ANC) >= 2,000/μL; platelets count >= 100,000/μL; hemoglobin must be >= 10 g/dL (can be corrected by growth factor or transfusion).
- •Adequate hepatic function defined as: serum bilirubin =< 1.5-fold upper limit of normal (ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) =< 3-fold ULN (5-fold ULN if liver metastasis is observed).
- •Adequate renal function with: serum creatinine =< 1.3 mg/dL or calculated creatinine clearance >= 60 mL/minute according to the Cockcroft and Gault formula.
- •At least one measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.
- •Women must be either of non-child bearing potential, or women with child-bearing potential agree to use effective a highly contraceptive method or a contraceptive implant, exception of hormonal contraception (estrogen/progesterone), during treatment from time of Screening Visit and after cessation of therapy at least 3 months.
- •Planning to receive Gemcitabine monotherapy.
- •Willing and able to comply with all aspects of the treatment protocol.
- •Provide written informed consent.
- •Exclusion Criteria:
- •Patients with following treatment prior to Gemcitabine monotherapy: chemotherapy, immunotherapy, or biologic systemic anticancer therapy within 28 days of study entry.
- •Pancreatic patients with prior history of Gemcitabine chemotherapy.
- •Women who are pregnant or breastfeeding.
- •Patients with brain metastasis.
- •Patients with bone metastasis alone.
- •Patients with autoimmune disease that requires systemic steroids or immunosuppression agents.
- •Current enrollment in another clinical study or used any investigational drug or device within the past 28 days preceding informed consent.
- •Known history of human immunodeficiency virus (HIV) infection.
- •Existing anticancer treatment-related toxicities of Grades >= 2 (except for alopecia and neuropathy) according to Common Terminology Criteria for Adverse Events (CTCAE v4.03).
- •Patients with an active infection requiring systemic therapy.
- •Patients are hepatitis C virus (HCV) carrier, and/or with active viral disease which is defined as hepatitis B virus (HBV) carrier with HBV DNA > 2,000 IU/ml plus AST and ALT > 3-fold ULN.
- •History of concomitant medical conditions or infectious diseases that, in the opinion of the investigator, would compromise the patient's ability to safely complete the study.
- •Ascertained hypersensitivity to investigational product, Gemcitabine or any of the excipients used in the study.
- •Uncontrolled nausea or vomiting or any symptom that would prevent the ability to comply with daily BLEX 404 Oral Liquid treatment.
- •Judged to be not applicable to this study by investigator such as difficulty of follow-up observation, psychiatric disorder, with any other serious diseases/medical history.
研究组 & 干预措施
BLEX 404 Oral Liquid
Experimental
During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
干预措施: BLEX 404 (Drug)
结局指标
主要结局
Part I: Dose-limiting toxicity (DLT) observation
时间窗: 4 weeks (1 cycle)
Presence or absence of dose-limiting toxicity (DLT) related to BLEX 404 Oral Liquid for each patient during first cycle of Gemcitabine monotherapy to determine the recommended dose level (RDL).
Part II: Overall response rate (PR + CR)
时间窗: 12 weeks (3 cycle)
Overall response rate (PR + CR) after 4 cycles of combination use in BLEX 404 + Gemcitabine monotherapy.
次要结局
- Part II: Incidence of grade 3/4 hematological toxicity(4 weeks (1 cycle))
- Part II: Overall benefit rate (CR + PR + SD)(12 weeks (3 cycle))
研究者
相似试验
终止
1 期
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Relapsed/Refractory Peripheral T-cell LymphomaNCT05403450Taiho Oncology, Inc.33
终止
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological MalignanciesAdvanced Nonhematological NeoplasmsNCT03370302Calithera Biosciences, Inc28
撤回
1 期
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Relapsed and/or Refractory Multiple MyelomaNCT04392648Teva Branded Pharmaceutical Products R&D LLC
已完成
1 期
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerHER2 Positive Metastatic Breast CancersNCT02025192Seagen Inc.60
招募中
2 期
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)Pulmonary Arterial HypertensionNCT05587712Merck Sharp & Dohme LLC42